On December 16, 2025, VaMPiRE hosted its annual assembly online to review the work carried out over the past year and to align all collaborators on recent developments and upcoming changes.
Among these changes, two new partners joined the VaMPiRE project. Sapienza University of Rome (UNIROMA1) replaced the Spitalul Universitar De Urgenta Bucuresti (SUUB) in clinical activities, while LEITAT, a Spanish technology center with strong expertise in both research and product engineering, joined to help translate research outcomes into market-ready in vitro diagnostic (IVD) devices.
Three new advisory board members were also appointed. José María Martínez, a recognized expert in ethics applied to R&D and large EU-funded projects, was appointed the Independent Ethical Advisor. Carles Puente Baliarda, Professor at the Universitat Politècnica de Catalunya, was appointed the Intellectual Property Strategist. Sonia Sarroca, Associate at Vidal-Quadras & Ramón, was appointed the In-house Project IP Legal Attorney.
In addition, Linkcare, the project lead of VaMPiRE, announced new additions to its leadership team. Bob Jenkins joined as CEO, bringing more than 30 years of experience in the in vitro diagnostics industry at large companies such as Werfen, as well as a background in neuroscience. Effie Wu also joined as Marketing Associate, with prior experience at Apple and the European Union Chamber of Commerce in China.
The consortium then reviewed progress against the project plan, the deliverables submitted in 2025, and the project’s financial status.
Linkcare also shared the latest updates on exploitation activities and intellectual property management related to VaMPiRE’s potential results.
Finally, the consortium confirmed that the next General Assembly will be held on March 9, 2026.
